Marshall Wace LLP Has $239,000 Position in Alector, Inc. (NASDAQ:ALEC)

Marshall Wace LLP lessened its stake in Alector, Inc. (NASDAQ:ALEC) by 70.3% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 52,609 shares of the company’s stock after selling 124,669 shares during the period. Marshall Wace LLP’s holdings in Alector were worth $239,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Gladius Capital Management LP bought a new stake in Alector in the 2nd quarter valued at $29,000. Allspring Global Investments Holdings LLC acquired a new position in Alector in the first quarter worth about $40,000. Lazard Asset Management LLC bought a new position in Alector during the first quarter worth about $59,000. China Universal Asset Management Co. Ltd. lifted its stake in Alector by 89.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 18,403 shares of the company’s stock worth $111,000 after purchasing an additional 8,670 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in Alector by 24.1% during the first quarter. ProShare Advisors LLC now owns 19,709 shares of the company’s stock valued at $119,000 after purchasing an additional 3,827 shares in the last quarter. 85.83% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alector

In other Alector news, CFO Marc Grasso sold 7,297 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $35,609.36. Following the sale, the chief financial officer now owns 130,740 shares of the company’s stock, valued at $638,011.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Alector news, CFO Marc Grasso sold 7,297 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $35,609.36. Following the completion of the transaction, the chief financial officer now directly owns 130,740 shares of the company’s stock, valued at approximately $638,011.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Sara Kenkare-Mitra sold 13,926 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $67,958.88. Following the completion of the transaction, the insider now directly owns 291,715 shares of the company’s stock, valued at approximately $1,423,569.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 58,222 shares of company stock valued at $286,013 over the last ninety days. 9.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ALEC. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Alector in a report on Thursday, June 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a research note on Tuesday, September 17th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $17.75.

Alector Trading Up 5.5 %

NASDAQ:ALEC opened at $4.80 on Friday. The stock has a market capitalization of $467.14 million, a P/E ratio of -2.67 and a beta of 0.68. Alector, Inc. has a 1 year low of $3.66 and a 1 year high of $8.90. The firm has a 50 day moving average of $5.11 and a 200-day moving average of $5.22.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. The firm had revenue of $15.08 million during the quarter, compared to analysts’ expectations of $16.04 million. Alector had a negative return on equity of 102.63% and a negative net margin of 290.66%. During the same period last year, the firm posted $0.02 EPS. As a group, analysts forecast that Alector, Inc. will post -1.92 EPS for the current fiscal year.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.